FOXN3

Across TCGA pan-cancer cohorts, FOXN3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FOXN3 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher FOXN3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXN3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

CHOL, UCEC, and BLCA are the cancer types where FOXN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.100	0.496	.006	21	view →
UCEC	DFS	Median	II,III,IV	0.882	0.434	.028	10	view →
BLCA	DFS	Median	II,III,IV	1.000	0.608	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FOXN3–CHOL (DFS)

Open the CHOL breakdown →